Capnat
Developed to target cancerous growths by utilizing systemic conversion to therapeutic agents that inhibit DNA synthesis.
Strengths: 500mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Xeloda
- Therapeutic class
Antineoplastic Agent; Antimetabolite
- Pharmacological class
Pyrimidine Analogue
- Minor side effects
diarrhoea; nausea; stomatitis; fatigue
- Moderate side effects
palmar-plantar erythrodysaesthesia; neutropenia; anaemia; dermatitis
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Natco Pharma
- Onset Time
N/A
- Duration
N/A
- Storage instructions
Store at room temperature below 30°C.
- Drug interactions
warfarin; phenytoin; folinic acid
- Age restrictions
Adults only.
- Pregnancy and breastfeeding
Pregnancy: Contraindicated. Breastfeeding: Contraindicated.
Contraindications
hypersensitivity to capecitabine; severe renal impairment; dihydropyrimidine dehydrogenase deficiency
Precautions and warnings
monitor for diarrhoea; risk of hand-foot syndrome; regular blood monitoring recommended
Serious side effects
severe dehydration — requires immediate medical attention; cardiotoxicity — requires immediate medical attention
Patient summary
Developed to target cancerous growths by utilizing systemic conversion to therapeutic agents that inhibit DNA synthesis.
Mechanism of action
Capecitabine is a prodrug that is enzymatically converted to 5-fluorouracil (5-FU) in the body, primarily within the tumour, where it inhibits thymidylate synthase and incorporates into RNA to block cell division.
Capnat
Developed to target cancerous growths by utilizing systemic conversion to therapeutic agents that inhibit DNA synthesis.
Editorial Notes
- Active ingredient(s): Capecitabine
- Listed indication(s): Colorectal Cancer, Breast Cancer
Available option
- 100 tablets - 500 mg1025-500-mg-12855